

1           **Targeted Quantitative Plasma Metabolomics Identifies Metabolite Signatures that**  
2           **Distinguish Heart Failure with Reduced and Preserved Ejection Fraction**

3  
4           Fawaz Naeem, BA<sup>1</sup>, Teresa C. Leone, BS<sup>1</sup>, Christopher Petucci, PhD<sup>1</sup>, Clarissa Shoffler, BS<sup>1</sup>,  
5           Ravindra C. Kodihalli, PhD<sup>3</sup>, Tiffany Hidalgo, MS<sup>4</sup>, Cheryl Tow-Keogh, MS<sup>4</sup>, Jessica Mancuso,  
6           PhD<sup>5</sup>, Iphigenia Tzamelis, PhD<sup>5</sup>, Donald Bennett, PhD<sup>5</sup>, John D. Groarke, MD<sup>6</sup>, Rachel J. Roth  
7           Flach, PhD<sup>6</sup>, Daniel J. Rader, MD<sup>1,2</sup>, Daniel P. Kelly, MD<sup>1\*</sup>

8  
9  
10           Cardiovascular Institute, Departments of <sup>1</sup>Medicine and <sup>2</sup>Genetics, Perelman School of  
11           Medicine, University of Pennsylvania, Philadelphia, PA; <sup>3</sup>Drug Safety R&D and <sup>4</sup>Translational  
12           Clinical Sciences, Pfizer Inc, Groton, CT; <sup>5</sup>Early Clinical Development and <sup>6</sup>Internal Medicine  
13           Research Unit, Pfizer Inc, Cambridge MA

14  
15  
16  
17  
18  
19  
20  
21  
22  
23           **Short Title:** Metabolic Signatures of HFrEF and HFpEF

24  
25           **Total Word Count:** 6526

26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40           \*Corresponding Author:  
41           Daniel P. Kelly, M.D.  
42           Perelman School of Medicine, University of Pennsylvania  
43           3400 Civic Center Blvd.  
44           Smilow Translational Research Center, Room 11-122  
45           Philadelphia, PA 19104  
46           dankelly@pennmedicine.upenn.edu

47 **Abstract**

48 **Background.** Two general phenotypes of heart failure (HF) are recognized: HF with reduced  
49 ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop HF disease phenotype-  
50 specific approaches to define and guide treatment, distinguishing biomarkers are needed. The  
51 goal of this study was to utilize quantitative metabolomics on a large, diverse population to  
52 replicate and extend existing knowledge of the plasma metabolic signatures in human HF.

53  
54 **Methods.** Quantitative, targeted LC/MS plasma metabolomics was conducted on 787 samples  
55 collected by the Penn Medicine BioBank from subjects with HFrEF (n=219), HFpEF (n=357),  
56 and matched non-failing Controls (n=211). A total of 90 metabolites were analyzed, comprising  
57 28 amino acids, 8 organic acids, and 54 acylcarnitines. 733 of these samples were also processed  
58 via an OLINK protein panel for proteomic profiling.

59  
60 **Results.** Consistent with previous studies, unsaturated forms of medium/long chain  
61 acylcarnitines were elevated in the HFrEF group to a greater extent than the HFpEF group  
62 compared to Controls. A number of amino acid derivatives, including 1- and 3-methylhistidine,  
63 homocitrulline, and symmetric (SDMA) and asymmetric (ADMA) dimethylarginine were  
64 elevated in HF, with ADMA elevated uniquely in HFpEF. Plasma branched-chain amino acids  
65 (BCAA) were not different across the groups; however, short-chain acylcarnitine species  
66 indicative of BCAA catabolism were significantly elevated in both HF groups. The ketone body  
67 3-hydroxybutyrate (3-HBA) and its metabolite C4-OH carnitine were uniquely elevated in the  
68 HFrEF group. Linear regression models demonstrated a significant correlation between plasma  
69 3-HBA and NT-proBNP in both forms of HF, stronger in HFrEF.

70 **Conclusions.** These results identify plasma signatures that are shared as well as potentially  
71 distinguish between HFrEF and HFpEF. Metabolite markers for ketogenic metabolic re-  
72 programming in extra-cardiac tissues were identified as unique signatures in the HFrEF group,  
73 possibly related to the lipolytic action of increased levels of BNP. Future studies will be  
74 necessary to further validate these metabolites as HF biosignatures that may guide phenotype-  
75 specific therapeutics and provide insight into the systemic metabolic responses to HFpEF and  
76 HFrEF.

## 77 **Clinical Perspective**

### 78 What Is New?

- 79 • “Real world” targeted metabolomic profiling on wide range of metabolites in a diverse  
80 population of patients with HFrEF and HFpEF.
- 81 • Levels of 3-hydroxybutyrate and its metabolite C4OH-carnitine were uniquely increased in  
82 the HFrEF group and correlated with levels of plasma NT-proBNP in both the heart failure  
83 groups, indicating the possibility of a heart-adipose-liver axis.
- 84 • Asymmetric dimethylarginine, a known inhibitor of nitric oxide synthase, was uniquely  
85 upregulated in HFpEF suggesting that there may also be an underlying component of  
86 vascular dysregulation contributing to HFpEF pathophysiology.

87

### 88 What Are the Clinical Implications?

- 89 • The plasma metabolomic changes seen in the heart failure cohorts support the existing theory  
90 of metabolic reprogramming, providing further rationale for the pursuit of therapeutic targets  
91 for the treatment of heart failure.
- 92 • Quantitative metabolomic profiling shows promise for guiding therapeutic decisions in  
93 HFrEF and HFpEF.
- 94 • Modulation of natriuretic peptides may enhance the delivery of ketone and fatty acids to the  
95 “fuel starved” failing heart.

96 **Non-standard Abbreviations and Acronyms:**

97		
98	HF	heart failure
99		
100	HFrEF	heart failure with reduced ejection fraction
101		
102	HFpEF	heart failure with preserved ejection fraction
103		
104	FAO	fatty acid oxidation
105		
106	FA	fatty acid
107		
108	FFA	free fatty acid
109		
110	AC	acylcarnitine
111		
112	SCAC	short-chain acylcarnitines
113		
114	MCAC	medium-chain acylcarnitines
115		
116	LCAC	long-chain acylcarnitines
117		
118	BCAA	branched-chain amino acids
119		
120	3-HBA	3-hydroxybutyrate
121		
122	BHB	beta-hydroxybutyrate
123		
124	ADMA	asymmetric dimethylarginine
125		
126	SDMA	symmetric dimethylarginine
127		
128	BNP	brain/b-type natriuretic peptide
129		
130	NT-proBNP	N-terminal pro b-type natriuretic peptide
131		
132	Nitric Oxide Synthase	NOS
133		
134	aKG	alpha-ketoglutarate
135		
136		
137		
138		

139 **Introduction**

140 Despite recent advances in treatment, heart failure (HF) remains a major cause of cardiovascular  
141 mortality worldwide and has a profound impact on functionality and quality of life.<sup>1</sup> HF is a  
142 broad clinical syndrome encompassing a heterogeneous group of diseases defined, in part, by  
143 degree of ventricular functional impairment and remodeling. While there is some debate  
144 regarding classification, two predominant phenotypes are recognized: HF with reduced ejection  
145 fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).<sup>2</sup> Our understanding of the  
146 pathogenic drivers that distinguish among these HF groups is incomplete, and therefore  
147 treatment regimens are generally not tailored to HF phenotype. Accordingly, identification of  
148 specific biosignatures to delineate distinct HF phenotypes is an important unmet need and could  
149 ultimately assist in the development of disease phenotype-targeted therapeutics.

150 Unbiased transcriptomic, metabolomic and/or proteomic profiling of myocardial tissues  
151 have been conducted in preclinical (rodent) models of HFrEF.<sup>3-6</sup> The results of these  
152 metabolomic profiling studies are consistent with the known shifts in myocardial fuel utilization  
153 that occur in HFrEF, including reduced capacity for mitochondrial fatty acid oxidation (FAO)<sup>7-13</sup>  
154 as reflected, in part, by reduced levels of ventricular medium- (MCAC) and long-chain  
155 acylcarnitines (LCAC), intermediates generated in the mitochondrial  $\beta$ -oxidation of fatty acids  
156 (FAs). Cardiac metabolomic analyses in pre-clinical models of HF have also identified  
157 signatures of decreased catabolism of branched-chain amino acids (BCAAs)<sup>3,14,15</sup> and increased  
158 oxidation of ketone bodies<sup>5</sup> in HFrEF myocardium, the latter likely used as an ancillary fuel in  
159 the context of diminished utilization of FA, the chief fuel of the normal adult heart. A small  
160 number of myocardial tissue-based metabolomic analyses in humans with HFrEF have also been  
161 reported.<sup>16-18</sup> The results of these studies are consistent with the pre-clinical studies

162 demonstrating reduced MCAC/LCAC and shorter-chain ACs indicative of reduced BCAA  
163 degradation. In addition, one study using endomyocardial biopsies in HFpEF patients and post-  
164 transplant or donor heart tissue in HFrEF patients demonstrated signatures of reduced  
165 MCAC/LCAC in both HFrEF and HFpEF along with increased levels of the ketone body, 3-  
166 hydroxybutyrate (3-HBA), in the HFrEF myocardium.<sup>18</sup> Lastly, a recent seminal study in which  
167 metabolites were collected from both systemic arterial and coronary sinus in humans to assess  
168 myocardial extraction levels found that the FA utilization was decreased and ketone utilization  
169 increased in humans with HFrEF compared to normal controls.<sup>19</sup>

170 A number of studies have assessed plasma metabolomics in humans with HF,  
171 particularly HFrEF, with a few studies comparing HFrEF and HFpEF.<sup>18,20-22</sup> The majority of  
172 HFrEF studies have shown an increase in circulating MCAC and LCAC.<sup>18,20,21,23,24</sup> This is a  
173 rather surprising finding given that these metabolites are reduced in HFrEF myocardium,  
174 suggesting that the origin of these species are likely extra-cardiac. The limited data available in  
175 which the plasma metabolome from HFrEF and HFpEF patients have been compared is  
176 conflicting, likely related to phenotypic heterogeneity and relatively low subject numbers.<sup>18,20</sup>  
177 For example, information on plasma levels of BCAA and ketone bodies are inconclusive.  
178 Zordoky et al. found that plasma ketones were increased in HFpEF to a greater extent than  
179 HFrEF.<sup>21</sup> A larger study conducted by Hunter et al. found no changes in ketone and ketone-  
180 related metabolites in the plasma of HF versus controls.<sup>20</sup> They also found that BCAAs and their  
181 metabolites were uniquely upregulated in HFrEF. In contrast, Hahn et al. recently found that  
182 circulating ketone bodies were elevated in HFrEF compared to HFpEF patients, with minimal  
183 changes in BCAAs.<sup>18</sup> In addition to these targeted plasma studies, there have been several studies

184 that have utilized untargeted metabolomics to identify potential biomarker panels that predict HF  
185 severity and mortality.<sup>25-27</sup>

186         Given the relative paucity and conflicting data regarding circulating metabolites in  
187 HFrEF versus HFpEF, we sought to conduct a study in a relatively large and diverse population  
188 of humans with HFrEF, HFpEF, and corresponding controls without HF in order to replicate and  
189 extend existing knowledge regarding potential distinguishing biosignatures. Notably, most of the  
190 studies cited above lacked large study populations and racial/ethnic diversity. In this study, we  
191 conducted quantitative plasma metabolomics and targeted proteomics on a large, diverse sample  
192 of patients. We collected samples in the ad lib fed state with an aim towards identifying markers  
193 that show promise for “real world” application. Our results indicate that a significant subset of  
194 unsaturated MCAC and LCAC were increased uniquely in the HFrEF group. In addition,  
195 circulating metabolites indicative of ketogenesis and ketone oxidation were significantly  
196 increased in HFrEF but not HFpEF. Methylated derivatives of arginine were shown to be  
197 elevated in HF, with asymmetric dimethylarginine increased uniquely in the HFpEF group.  
198 Lastly, BCAA levels were not different among the groups but metabolites indicative of BCAA  
199 catabolism were increased in both HFrEF and HFpEF.



200 **Methods**

201

202 **Study Population**

203 The present study employed the Penn Medicine Biobank registry to identify anonymized patient  
204 data and plasma samples. The Biobank is a research program at the University of Pennsylvania  
205 in which enrolled participants provide consent for research, access to their medical records,  
206 genetic data, and blood samples. The Biobank was systematically reviewed to identify patients  
207 meeting specific inclusion criteria for 1 of 3 groups: HFrEF, HFpEF, or control. Inclusion  
208 criteria for the HFrEF group was defined as patients with a clinical diagnosis of HF and an  
209 ejection fraction of less than 35%. The HFpEF group consisted of patients with a clinical  
210 diagnosis of HF, an ejection fraction greater than 45%, and an H2FPEF score<sup>28</sup> greater than 4,  
211 giving a probability of 70% or higher. Patients with HF secondary to hypertrophic  
212 cardiomyopathy, restrictive cardiomyopathy, amyloidosis, or valvular disease were excluded  
213 from the study. The control group was generated by matching to the HFpEF group for gender,  
214 race, age, and comorbid diagnoses of hypertension and diabetes. Exclusion criteria for the  
215 control group included HF of any etiology, cancer diagnosis in the last 5 years, any autoimmune  
216 disease, cirrhosis, nonalcoholic steatohepatitis, chronic obstructive pulmonary disease, or  
217 idiopathic pulmonary fibrosis.

218

219 **Targeted Metabolomics**

220 The Biobank obtained plasma samples of enrolled patients during routine outpatient phlebotomy  
221 appointments. Fasting was not a requirement for sampling. Samples were obtained between  
222 2008-2022 and were stored in a -80°C freezer. Following screening of the Biobank and  
223 identification of eligible patients, corresponding plasma samples were obtained and sent to the  
224 Penn Metabolomics Core for targeted metabolomic analysis. From the plasma samples, aliquots

225 (50-100  $\mu$ L) were extracted for ACs, amino acids, and organic acids according to validated,  
226 optimized protocols as described.<sup>23</sup> Each class of metabolites was separated with a unique high-  
227 performance liquid chromatography (HPLC) method to optimize their chromatographic  
228 resolution and sensitivity. Quantitation of metabolites in each assay module was achieved using  
229 multiple reaction monitoring of calibration solutions and study samples on an Agilent 1290  
230 Infinity UHPLC/6495B triple quadrupole mass spectrometer. Raw data was processed using  
231 Mass Hunter quantitative analysis software (Agilent). Calibration curves ( $R^2 = 0.99$  or greater)  
232 were either fitted with a linear or a quadratic curve with a 1/X or 1/X<sup>2</sup> weighting.

233 Plasma levels of NT-proBNP were profiled using the Target 96 Cardiovascular III panels  
234 (Product #95611A, Lot #B24627A; corresponding detection and controls, Product #95611B, Lot  
235 #B24627B) using Olink technologies ([www.olink.com](http://www.olink.com); Watertown, MA) by Pfizer, Inc.<sup>29</sup> This  
236 panel allows simultaneous analysis of 92 protein biomarkers with documented or suggested  
237 involvement in cardiovascular processes or diseases using 1  $\mu$ L of sample volume. A total of 733  
238 (eight batches of 88 and one batch of 29) K2 EDTA plasma samples were randomly distributed  
239 across 9 plates, and protein analyses were performed by trained technicians blinded to the  
240 clinical information. Any failed sample in a given batch or outlier samples were included in the  
241 last batch of samples. Each analysis plate, consisting of 96 wells, included two sample controls  
242 to assess coefficient precision, three negative controls to establish background levels for each  
243 protein assay and calculate the detection limit, and three inter-plate controls to adjust for any  
244 variations between runs and plates. The samples were analyzed according to the protocol  
245 provided by Olink.

246  
247 **Statistical Analyses**

248 A total of 90 metabolites were analyzed, comprising 28 amino acids, 8 organic acids, and 54  
249 ACs, which were further classified into short, medium, long, and very-long chain ACs.  
250 Metabolites for which greater than 50% of the samples returned above or below the limit of  
251 quantification were excluded from the analysis. Statistical comparisons between metabolites and  
252 clinical biomarkers were performed using One-Way ANOVA with multiple comparisons.  
253 Comorbidity and demographic comparisons were conducted using Fischer's exact test. Radar  
254 plots were generated in Visual Studio using the ChartJS software. Linear regression models with  
255 an OLINK Protein Panel, including NTproBNP, as the response variable were used to explore  
256 mean differences between HFpEF, HFrEF, and controls as well with covariates including race,  
257 sex, age, BMI, MI, ischemia, T2 diabetes, hypertension, hyperlipidemia, atrial fibrillation,  
258 stroke, sleep apnea, and chronic kidney disease. Tukey's adjustment was used for multiple  
259 comparisons within an independent variable. Histograms, QQ plots, and the Shapiro-Wilks test  
260 were used to assess the normality assumption.  
261

## 262 **Results**

263

### 264 **Clinical and Demographic Characteristics of the Study Cohorts**

265 The clinical and demographic characteristics of the study population are shown in Tables 1 and  
266 2. Age and racial breakdown were comparable across all three groups (Table 2). Notably, the  
267 HF<sub>r</sub>EF cohort exhibited a male predominance (Table 2). BMI was significantly higher in the  
268 HF<sub>p</sub>EF cohort compared to the other two groups (Table 1). The HF<sub>r</sub>EF cohort had significantly  
269 lower mean systolic and diastolic blood pressure, as well as an elevated mean heart rate (Table  
270 1). Type 2 diabetes hypertension, hyperlipidemia, prior MI, CKD, and atrial fibrillation were  
271 significantly higher in the HF groups compared to controls (Table 2). Atrial fibrillation and Type  
272 2 diabetes were both higher in HF<sub>p</sub>EF versus HF<sub>r</sub>EF (Table 2).

273

### 274 **Fatty Acid Metabolism: Medium- and Long-chain ACs**

275 ACs, intermediates of FAO, were grouped into short-chain (C2-C6, SCAC), MCAC (C8-C12),  
276 LCAC (C14-C18), and very long-chain (C20-C22, VLCAC) species. In alignment with prior  
277 studies,<sup>18,20,21,23,24</sup> the majority of unsaturated MCAC and LCAC exhibited elevation in the  
278 HF<sub>r</sub>EF group (Figure 1). These include C8:1-OH, C12-OH, C14:1, C14:1-OH, C14:2, C14-OH,  
279 C16:1, C16:1-OH, C16:2-OH, C18:1, C18:1-OH, C18:2, C20:1, and C20:2. Conversely, the  
280 saturated MCAC/LCAC/VLCAC species (C8, C10, C12, C14, C16, C18, C20) were not  
281 different across the groups (Figure 1). Few ACs were changed in HF<sub>p</sub>EF.

282

### 283 **Amino Acid Metabolism: Amino Acids and Amino Acid Derivatives**

284 BCAAs were not elevated in the HF groups in contrast to other reports<sup>14,20,21</sup> (Figure 2). Rather,  
285 levels of leucine were reduced. Notably, however, a number of SCACs that are generated via  
286 BCAA degradation were elevated in the plasma of both HF groups (Figure 2). For example,

287 C04-DC methylmalonyl carnitine and C04-DC succinyl carnitine, common downstream  
288 metabolites of the degradation of all three BCAAs, were elevated in the plasma of both HF  
289 groups against control. C04 isobutyryl carnitine demonstrated a similar pattern. C04-OH  
290 isobutyryl, C05-2-methylbutyryl, C05:1, C05-OH, and C06-OH carnitines exhibited stepwise  
291 elevation, highest in HFrEF (Figure 2).

292 A number of amino acid metabolites exhibited notable changes in the HF groups. 1-  
293 methylhistidine demonstrated a stepwise increase across the HF groups, with highest levels in the  
294 HFrEF cohort (Figure 3). 3-methylhistidine was similarly elevated in the two HF groups  
295 compared to control. Two arginine derivatives known to regulate the biosynthesis of nitric oxide  
296 were also increased in the HF groups: asymmetric dimethylarginine (ADMA) and symmetric  
297 dimethylarginine (SDMA) (Figure 4A). SDMA was significantly elevated in both HF groups  
298 whereas ADMA, a direct inhibitor of nitric oxide synthase,<sup>30</sup> was uniquely elevated in HFpEF.  
299 Arginine was unchanged across the groups (Figure 4B). In addition, mean plasma homocitrulline  
300 levels were increased in both HF groups, and were more than doubled in the HFrEF group over  
301 control (Figure 4D). Citrulline, kynurenine, phenylalanine, and tyrosine were also elevated in  
302 both forms of HF compared to control (Figure 3).

303

### 304 **Tricarboxylic Acid Cycle (TCA) and Ketone Metabolism: Organic Acids**

305 TCA metabolites citrate, succinate, fumarate, and malate were mildly but significantly elevated  
306 in the plasma of both HF groups (Figure 5A). The most notable elevations in the organic acid  
307 category were observed for alpha-ketoglutarate and 3-HBA, which were both uniquely elevated  
308 in HFrEF. In addition, C4-OH carnitine, a metabolite downstream of 3-HBA oxidation, was  
309 similarly uniquely elevated in HFrEF (Figure 5B).

310

### 311 **Correlation of NT-proBNP with 3-HBA and C4-OH Carnitine**

312 The observation that 3-HBA is uniquely elevated in the HFrEF group strongly suggests that  
313 hepatic ketogenesis is increased in this group. In addition, elevation of C4-OH carnitine in the  
314 HFrEF group is a marker of increased ketone body oxidation. An increase in circulating ketone  
315 bodies has been described in HFrEF patients<sup>5,16,18,31,32</sup> but the underlying mechanism that links  
316 HF to increased hepatic ketogenesis is unknown. Ketosis often occurs in the context of increased  
317 free FA delivery to the liver, secondary to adipose lipolysis. Previous studies have indeed shown  
318 increased plasma free fatty acid (FFA) levels in patients with HFrEF.<sup>33-35</sup> Given that natriuretic  
319 peptides are known to increase lipolysis, we hypothesized that BNP-mediated lipolysis may lead  
320 to increased hepatic ketogenesis in the HFrEF group.<sup>36</sup> NT-proBNP levels were elevated in both  
321 forms of HF compared to controls with significantly higher levels in the HFrEF group (Figure  
322 6A). Notably, hypertension and diabetes had no significant impact on NT-proBNP levels. In  
323 linear regression models, a positive correlation between 3-HBA and NT-proBNP was observed  
324 in both HFrEF and HFpEF, with the strongest association in the HFrEF cohort (Figure 6B).  
325 Notably, plasma 3-HBA and NT-proBNP were not significantly correlated in the control group.  
326 A similar pattern was seen for the ketone metabolite C4-OH carnitine (Figure S1). Taken  
327 together these results suggest a potential mechanism whereby increased natriuretic levels  
328 generated by the failing heart results in lipolysis and increased delivery of FFA to the liver,  
329 which in turn increases FAO and ketogenesis (Figure 6C).

330

331

## 332 **Discussion**

333 This study identifies several novel findings and reinforces previous findings regarding  
334 comparative plasma metabolite levels in patients with HFrEF, HFpEF, and controls without HF  
335 in a relatively large and diverse population using targeted quantitative metabolomics. The  
336 samples were collected in a manner in which time of last meal was not controlled, enhancing the  
337 potential for application to biomarker discovery and development. Our results confirmed the  
338 results of previous studies as well as identified new metabolite markers of HF, including both  
339 shared and HF phenotype-specific signatures. First, as has been described, we found that  
340 circulating MCACs, LCACs, and the ketone body 3-HBA were increased in patients with HFrEF  
341 compared to HFpEF and controls.<sup>18,20,21,23,24,31</sup> Second, in contrast to a few published studies,<sup>14,20</sup>  
342 BCAA levels were not different among the groups but metabolites of BCAA degradation were  
343 increased in both HFrEF and HFpEF. Third, our results identify a number of interesting novel  
344 amino acid metabolite signatures including elevation of methylated amino acid derivatives in  
345 both HF groups. Furthermore, a methylated arginine derivative, asymmetric dimethylarginine,  
346 was increased uniquely in the HFpEF group. Lastly, we find that the levels of circulating NT-  
347 proBNP correlated with 3-HBA and C4-OH carnitine across the heart failure groups, suggesting  
348 a potential axis between the failing heart, adipose tissue, and the liver.

349 This study corroborates several previous studies that have found LCACs to be elevated in  
350 the plasma of patients with HF. More specifically, we found that a large subset of unsaturated  
351 MCAC and LCACs were uniquely elevated in HFrEF. Very few of these species were  
352 significantly changed from control in HFpEF. Our findings are most similar to those of Hunter et  
353 al.<sup>20</sup> and Hahn et al,<sup>18</sup> in which ACs were found to be elevated in HF, with highest levels in  
354 HFrEF compared to HFpEF. Furthermore, two independent studies investigating the plasma of

355 patients with ischemic HF and diminished EF, patients that would mostly be described in the  
356 current HF schema as HFrEF, found that the HF groups had significantly elevated ACs across  
357 various chain lengths.<sup>23,24</sup> On the other hand, some studies have reported elevation of AC species  
358 in HFpEF greater than HFrEF.<sup>21,22</sup> A unique pattern in our acylcarnitine profile was the  
359 consistency with which saturated species were unchanged in either form of HF. This pattern has  
360 only been reported once before in a small subset of patients with end-stage dilated  
361 cardiomyopathy.<sup>17</sup> The basis for this observation is unclear but may reflect the composition of  
362 the triglyceride pool in the adipose tissue which in turn is influenced by diet. It is also possible  
363 that the activity of FA desaturases is reduced in some tissues in HFrEF.

364 While several preclinical models of HF have shown increased levels of circulating  
365 BCAAs,<sup>14,37</sup> human plasma metabolomic analyses have failed to consistently corroborate this  
366 finding. Hunter et al. found that BCAAs and related metabolites were uniquely elevated in the  
367 plasma of patients with HF.<sup>20</sup> Furthermore, in a combined preclinical and clinical study, Sun et  
368 al. found an increase in the circulating branched chain keto acid  $\alpha$ -keto- $\beta$ -methylvalerate.<sup>14</sup>  
369 However, our results, as well as those of Hahn et al., did not find a significant change in  
370 circulating BCAAs in humans with HF.<sup>18</sup> In fact, we found a modest downregulation of leucine  
371 in the HF groups. The reason for these varying findings remains unclear, but inconsistent dietary  
372 restriction and fasting status across the studies is likely a contributing factor. Furthermore, it is  
373 possible that other study populations had a greater prevalence of diabetes or insulin resistance in  
374 the HF cohorts compared to controls which could influence the results. Interestingly, we found a  
375 pattern of increased SCACs indicative of catabolism of BCAAs in the HF groups (Figure 2).  
376 This was also seen to some degree by Hahn et al.<sup>18</sup> This is a surprising finding given that  
377 transcriptomic and metabolomic studies of failing myocardium suggest reduced BCAA



378 degradation in HF.<sup>3,14,37</sup> Accordingly, the source of the increased BCAA oxidation is likely  
379 extra-cardiac such as skeletal muscle or liver. Notably, pharmacologic or genetic interventions  
380 that increase BCAA catabolism have been shown to improve or attenuate HF in mouse models of  
381 HF.<sup>14,37,38</sup> Future studies will be needed to further investigate the origin of these metabolites and  
382 what role they may play, compensatory or pathologic, in HF.

383         The panel of amino acid metabolites analyzed uncovered a number of interesting and  
384 novel findings. One particularly noteworthy finding was an elevation of ADMA, an arginine  
385 metabolite, uniquely in HFpEF. Its counterpart, SDMA, was elevated in both forms of HF. These  
386 species are known to interfere with nitric oxide synthesis by either directly or indirectly  
387 inhibiting nitric oxide synthase (NOS) (Figure 4A), contributing to worsening systemic  
388 vasoconstriction.<sup>30</sup> These species have also been found to be positively correlated with NT-  
389 proBNP and with increased severity of diastolic dysfunction in patients with HFpEF.<sup>39</sup> Whether  
390 they are involved as a driver of HF or merely a metabolic consequence of HF remains to be  
391 determined. Increased systemic vasoconstriction and cardiac afterload via NOS inhibition could  
392 contribute to pathologic myocardial hypertrophy that ultimately manifests as HF. Furthermore,  
393 coronary vasomotor disturbances could also be contributory.<sup>39</sup> Notably, increasing emphasis has  
394 been placed on the potential role of vascular dysregulation as a driver of HFpEF.<sup>40</sup> Further  
395 studies will be needed to determine whether ADMA and SDMA can be used as biosignatures for  
396 earlier identification of HFpEF and whether they can be utilized as targets for vascular  
397 modulation to ameliorate or prevent HF.

398         Homocitrulline was elevated in a stepwise fashion in the HF groups with the HFpEF  
399 group exhibiting over twice the mean plasma concentration of the control group. L-  
400 homocitrulline is an amino acid and a metabolite of ornithine metabolism. It is believed that the

401 depletion of the ornithine supply causes the accumulation of carbamyl-phosphate in the urea  
402 cycle which may be responsible for the enhanced synthesis of homocitrulline and  
403 homoarginine.<sup>41</sup> It is important to note that the homocitrulline measured in metabolomics assays  
404 is likely a combination of diet-based factors as well as a measure of protein carbamylation,  
405 which is the incorporation of cyanate residues into amino acids secondary to abundance of serum  
406 urea.<sup>42</sup> While homocitrulline has not been extensively studied in HF, it has been positively  
407 correlated with NT-proBNP as well as broadly implicated in cardiovascular disease, chronic  
408 kidney disease, atherosclerosis, and endothelial dysfunction.<sup>42,43</sup> We also found that 1- and 3-  
409 methylhistidine were elevated in the HF groups over control. These species have not been  
410 previously studied in HF. They are thought to be biomarkers of skeletal muscle protein turnover  
411 and toxicity.<sup>44</sup> Thus, they may be useful prognostic biomarkers that allow clinicians to determine  
412 the severity and decompensation of patients with HF.

413 Studies in humans have shown that HF triggers an increase in circulating ketone  
414 bodies.<sup>5,16,18,21,31,45</sup> In addition, evidence from our group and others ranging from pre-clinical  
415 studies to humans found that the failing heart shifts to utilizing ketone bodies as a compensatory  
416 ancillary fuel.<sup>5,16,19,46</sup> Our results are consistent with this, showing an increase in 3-HBA, also  
417 known as beta-hydroxybutyrate (BHB), and C4-OH carnitine in the HFrEF group. Hahn et al.  
418 similarly found increased ketogenesis in HFrEF as opposed to HFpEF.<sup>18</sup> However, other studies  
419 have found either no change in HF versus control<sup>20</sup> or have found that ketones are increased in  
420 HFpEF to a greater degree than HFrEF.<sup>21</sup> The mechanism whereby HF triggers hepatic  
421 ketogenesis in HF is unknown. Furthermore, it is unclear as to why 3-HBA levels are higher in  
422 HFrEF relative to HFpEF as observed in this study and by others. Natriuretic peptides are  
423 leading candidates for metabolic signaling from the failing heart. BNP is known to mediate

424 lipolysis,<sup>36</sup> and our results found that NT-proBNP was higher in HFrEF compared to HFpEF, as  
425 has been described previously.<sup>47</sup> Indeed we found a significant correlation between levels of NT-  
426 proBNP and 3-HBA and its downstream metabolite C4-OH carnitine in our HF cohorts. We  
427 hypothesize that the failing heart secretes BNP which ultimately drives increased lipolysis  
428 resulting in increased FFA delivery to the liver, which in turn increases FA oxidation (and  
429 increased production and secretion of MCACs and LCACs) and generates increased levels of  
430 acetyl-CoA, a substrate for ketogenesis (Figure 6C). This is most predominant in HFrEF given  
431 that NT-proBNP was most significantly upregulated in this group. Further studies will be needed  
432 in order to assess the degree to which ketosis in HF is BNP-dependent and whether this pathway  
433 can be harnessed for new therapeutic avenues.

#### 434 435 **Study Limitations**

436 In spite of the robust sample size, racial diversity, and wide metabolomic panel, this study has  
437 several limitations. Notably, by not controlling fasting status and using a singular plasma sample,  
438 our results are susceptible to day-to-day dietary variability. This is likely limited by the large  
439 sample size, however it remains a factor to consider. Additionally, the collection of plasma  
440 samples at routine outpatient visits ensures that the majority of the HF cohorts are likely well-  
441 compensated, which does not accurately reflect the totality of the HF population. Our controls  
442 were matched to the HFpEF group for comorbidities and demographics, which could possibly  
443 exaggerate the findings in the HFrEF group. Lastly, while we analyzed an extensive plasma  
444 metabolomic panel, these findings are provided without the context of corresponding myocardial  
445 tissue analysis, which ultimately would have contributed to the interpretation of our findings.

446  
447  
448

449 **Acknowledgements**

450  
451 Metabolomics studies were performed by the Metabolomics Core (RRID:SCR\_022381) in the  
452 Penn Cardiovascular Institute and supported, in part, by NCI P30 CA016520 and NIH P30  
453 DK050306-27. We thank Stephanie DerOhannessian for help with sample collection and  
454 preparation. We acknowledge the Penn Medicine BioBank (PMBB) for providing data and  
455 thank the patient-participants of Penn Medicine who consented to participate in this research  
456 program. The PMBB is approved under IRB protocol# 813913 and supported by Perelman  
457 School of Medicine at University of Pennsylvania, a gift from the Smilow family, and the  
458 National Center for Advancing Translational Sciences of the National Institutes of Health under  
459 CTSA award number UL1TR001878.

460

461  
462 **Source of Funding**

463  
464 DPK was supported by NIH R01 HL151345, R01 HL128349 (DPK) and Pfizer Co, Research  
465 Support.

466

467

468

469 **Disclosures**

470

471 DPK is a consultant for Pfizer, Ltd.

472

473 **References**

- 474 1. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of  
475 heart failure: a comprehensive and updated review of epidemiology. *Cardiovascular*  
476 *research*. 2022;118(17):3272-3287.
- 477 2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the  
478 management of heart failure: a report of the American College of Cardiology/American  
479 Heart Association Joint Committee on Clinical Practice Guidelines. *Journal of the*  
480 *American College of Cardiology*. 2022;79(17):e263-e421.
- 481 3. Lai L, Leone TC, Keller MP, et al. Energy metabolic reprogramming in the hypertrophied  
482 and early stage failing heart: a multisystems approach. *Circulation: Heart Failure*.  
483 2014;7(6):1022-1031.
- 484 4. Sansbury BE, DeMartino AM, Xie Z, et al. Metabolomic analysis of pressure-overloaded  
485 and infarcted mouse hearts. *Circulation: heart failure*. 2014;7(4):634-642.
- 486 5. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel.  
487 *Circulation*. 2016;133(8):698-705.
- 488 6. McKirnan MD, Ichikawa Y, Zhang Z, et al. Metabolomic analysis of serum and  
489 myocardium in compensated heart failure after myocardial infarction. *Life sciences*.  
490 2019;221:212-223.
- 491 7. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: gene  
492 regulatory mechanisms. *International journal of molecular medicine*. 1998;1(1):17-41.
- 493 8. Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED. Cardiac energy metabolism in  
494 heart failure. *Circulation research*. 2021;128(10):1487-1513.
- 495 9. Huss JM, Kelly DP. Mitochondrial energy metabolism in heart failure: a question of  
496 balance. *The Journal of clinical investigation*. 2005;115(3):547-555.
- 497 10. Taegtmeyer H, Wilson CR, Razeghi P, Sharma S. Metabolic energetics and genetics in the  
498 heart. *Annals of the New York Academy of Sciences*. 2005;1047(1):208-218.
- 499 11. Neubauer S. The failing heart—an engine out of fuel. *New England Journal of Medicine*.  
500 2007;356(11):1140-1151.
- 501 12. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the  
502 myocardial and systemic perspective. *Journal of the American College of Cardiology*.  
503 2014;64(13):1388-1400.
- 504 13. Ardehali H, Sabbah HN, Burke MA, et al. Targeting myocardial substrate metabolism in  
505 heart failure: potential for new therapies. *European journal of heart failure*.  
506 2012;14(2):120-129.
- 507 14. Sun H, Olson KC, Gao C, et al. Catabolic defect of branched-chain amino acids promotes  
508 heart failure. *Circulation*. 2016;133(21):2038-2049.
- 509 15. Wang W, Zhang F, Xia Y, et al. Defective branched chain amino acid catabolism  
510 contributes to cardiac dysfunction and remodeling following myocardial infarction.  
511 *American Journal of Physiology-Heart and Circulatory Physiology*. 2016;311(5):H1160-  
512 H1169.
- 513 16. Bedi Jr KC, Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of  
514 lipid metabolism and increased myocardial ketone utilization in advanced human heart  
515 failure. *Circulation*. 2016;133(8):706-716.
- 516 17. Flam E, Jang C, Murashige D, et al. Integrated landscape of cardiac metabolism in end-  
517 stage human nonischemic dilated cardiomyopathy. *Nature cardiovascular research*.  
518 2022;1(9):817-829.

- 519 18. Hahn VS, Petucci C, Kim M-S, et al. Myocardial metabolomics of human heart failure with  
520 preserved ejection fraction. *Circulation*. 2023;147(15):1147-1161.
- 521 19. Murashige D, Jang C, Neinast M, et al. Comprehensive quantification of fuel use by the  
522 failing and nonfailing human heart. *Science*. 2020;370(6514):364-368.
- 523 20. Hunter WG, Kelly JP, McGarrah III RW, et al. Metabolomic profiling identifies novel  
524 circulating biomarkers of mitochondrial dysfunction differentially elevated in heart failure  
525 with preserved versus reduced ejection fraction: evidence for shared metabolic impairments  
526 in clinical heart failure. *Journal of the American Heart Association*. 2016;5(8):e003190.
- 527 21. Zordoky BN, Sung MM, Ezekowitz J, et al. Metabolomic fingerprint of heart failure with  
528 preserved ejection fraction. *PloS one*. 2015;10(5):e0124844.
- 529 22. Hage C, Löfgren L, Michopoulos F, et al. Metabolomic profile in HFpEF vs HFrEF  
530 patients. *Journal of cardiac failure*. 2020;26(12):1050-1059.
- 531 23. Lanfear DE, Gibbs JJ, Li J, et al. Targeted metabolomic profiling of plasma and survival in  
532 heart failure patients. *JACC: Heart Failure*. 2017;5(11):823-832.
- 533 24. Ruiz M, Labarthe F, Fortier A, et al. Circulating acylcarnitine profile in human heart  
534 failure: a surrogate of fatty acid metabolic dysregulation in mitochondria and beyond.  
535 *American Journal of Physiology-Heart and Circulatory Physiology*. 2017;313(4):H768-  
536 H781.
- 537 25. Cheng M-L, Wang C-H, Shiao M-S, et al. Metabolic disturbances identified in plasma are  
538 associated with outcomes in patients with heart failure: diagnostic and prognostic value of  
539 metabolomics. *Journal of the American College of Cardiology*. 2015;65(15):1509-1520.
- 540 26. Dunn WB, Broadhurst DI, Deepak SM, et al. Serum metabolomics reveals many novel  
541 metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate.  
542 *Metabolomics*. 2007;3:413-426.
- 543 27. Deidda M, Piras C, Dessalvi CC, et al. Metabolomic approach to profile functional and  
544 metabolic changes in heart failure. *Journal of Translational Medicine*. 2015;13:1-11.
- 545 28. Reddy YN, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based  
546 approach to help guide diagnosis of heart failure with preserved ejection fraction.  
547 *Circulation*. 2018;138(9):861-870.
- 548 29. Assarsson E, Lundberg M, Holmquist G, et al. Homogenous 96-plex PEA immunoassay  
549 exhibiting high sensitivity, specificity, and excellent scalability. *PloS one*.  
550 2014;9(4):e95192.
- 551 30. Schlesinger S, Sonntag SR, Lieb W, Maas R. Asymmetric and symmetric dimethylarginine  
552 as risk markers for total mortality and cardiovascular outcomes: a systematic review and  
553 meta-analysis of prospective studies. *PloS one*. 2016;11(11):e0165811.
- 554 31. Lommi J, Kupari M, Koskinen P, et al. Blood ketone bodies in congestive heart failure.  
555 *Journal of the American College of Cardiology*. 1996;28(3):665-672.
- 556 32. Voros G, Ector J, Garweg C, et al. Increased cardiac uptake of ketone bodies and free fatty  
557 acids in human heart failure and hypertrophic left ventricular remodeling. *Circulation:  
558 Heart Failure*. 2018;11(12):e004953.
- 559 33. Lommi J, Kupari M, Yki-Järvinen H. Free fatty acid kinetics and oxidation in congestive  
560 heart failure. *The American journal of cardiology*. 1998;81(1):45-50.
- 561 34. Øie E, Ueland T, Dahl C, et al. Fatty acid composition in chronic heart failure: low  
562 circulating levels of eicosatetraenoic acid and high levels of vaccenic acid are associated  
563 with disease severity and mortality. *Journal of internal medicine*. 2011;270(3):263-272.



- 564 35. Zhu N, Jiang W, Wang Y, Wu Y, Chen H, Zhao X. Plasma levels of free fatty acid differ in  
565 patients with left ventricular preserved, mid-range, and reduced ejection fraction. *BMC*  
566 *Cardiovascular Disorders*. 2018;18:1-8.
- 567 36. Lafontan M, Moro C, Berlan M, Crampes F, Sengenès C, Galitzky J. Control of lipolysis  
568 by natriuretic peptides and cyclic GMP. *Trends in Endocrinology & Metabolism*.  
569 2008;19(4):130-137.
- 570 37. Li R, He H, Fang S, et al. Time series characteristics of serum branched-chain amino acids  
571 for early diagnosis of chronic heart failure. *Journal of proteome research*.  
572 2019;18(5):2121-2128.
- 573 38. Murashige D, Jung JW, Neinast MD, et al. Extra-cardiac BCAA catabolism lowers blood  
574 pressure and protects from heart failure. *Cell metabolism*. 2022;34(11):1749-1764. e7.
- 575 39. Pilz S, Edelmann F, Meinitzer A, et al. Associations of methylarginines and homoarginine  
576 with diastolic dysfunction and cardiovascular risk factors in patients with preserved left  
577 ventricular ejection fraction. *Journal of cardiac failure*. 2014;20(12):923-930.
- 578 40. Lyle MA, Brozovich FV. HFpEF, a disease of the vasculature: a closer look at the other  
579 half. Elsevier; 2018:1305-1314.
- 580 41. Monné M, Miniero DV, Daddabbo L, Palmieri L, Porcelli V, Palmieri F. Mitochondrial  
581 transporters for ornithine and related amino acids: a review. *Amino Acids*. 2015;47:1763-  
582 1777.
- 583 42. Tang WW, Shrestha K, Wang Z, et al. Protein carbamylation in chronic systolic heart  
584 failure: relationship with renal impairment and adverse long-term outcomes. *Journal of*  
585 *cardiac failure*. 2013;19(4):219-224.
- 586 43. Verbrugge FH, Tang WW, Hazen SL. Protein carbamylation and cardiovascular disease.  
587 *Kidney international*. 2015;88(3):474-478.
- 588 44. Aranibar N, Vassallo JD, Rathmacher J, et al. Identification of 1-and 3-methylhistidine as  
589 biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic  
590 profiling. *Analytical biochemistry*. 2011;410(1):84-91.
- 591 45. Du Z, Shen A, Huang Y, et al. 1H-NMR-based metabolic analysis of human serum reveals  
592 novel markers of myocardial energy expenditure in heart failure patients. *PloS one*.  
593 2014;9(2):e88102.
- 594 46. Horton JL, Davidson MT, Kurishima C, et al. The failing heart utilizes 3-hydroxybutyrate  
595 as a metabolic stress defense. *JCI insight*. 2019;4(4)
- 596 47. Kang S-H, Park JJ, Choi D-J, et al. Prognostic value of NT-proBNP in heart failure with  
597 preserved versus reduced EF. *Heart*. 2015;101(23):1881-1888.
- 598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609

610 **Table 1. Clinical Characteristics of the Study Population**  
611

	<b>Control</b>	<b>HFpEF</b>	<b>HFrEF</b>	<b>Control vs. HFpEF p-value</b>	<b>Control vs. HFrEF p-value</b>	<b>HFpEF vs. HFrEF p-value</b>
<b>n</b>	211	357	219		n/a	
<b>Age (Mean(SD))</b>	63.8(12.7)	65.2(11.5)	62.9(13.4)	0.3502	0.7684	0.0758
<b>Height (in)</b>	67.4(3.8)	67.1(4.5)	68.6(4.2)	0.7578	<b>0.019</b>	<b>0.0007</b>
<b>Weight (lbs)</b>	187(39.3)	216.5(56.9)	201.3(55.8)	<b>&lt;0.0001</b>	<b>0.0216</b>	<b>0.0056</b>
<b>BMI (kg/m<sup>2</sup>)</b>	28.9(5.5)	34.1(8.1)	29.7(7.1)	<b>&lt;0.0001</b>	0.5266	<b>&lt;0.0001</b>
<b>Systolic BP (mmHg)</b>	131.6(19.9)	130.4(19.6)	117.2(20.8)	0.79	<b>&lt;.0001</b>	<b>&lt;.0001</b>
<b>Diastolic BP (mmHg)</b>	76(10.9)	72.4(12.4)	69.4(15)	<b>0.0042</b>	<b>&lt;.0001</b>	<b>0.0192</b>
<b>Heart Rate (BPM)</b>	73(12.7)	77(15.8)	80.1(16.1)	<b>0.0089</b>	<b>&lt;.0001</b>	0.0925
<b>HBA1C (%)</b>	6.2(1.1)	6.6(1.5)	6.3(1.3)	0.068	0.8754	0.2019
<b>Serum Glucose (mg/dL)</b>	103.6(32.6)	121(48.4)	116.9(48.8)	<b>0.0001</b>	<b>0.0158</b>	0.697
<b>Creatinine (mg/dL)</b>	.99(.48)	1.4(1.2)	1.7(1.6)	<b>0.0008</b>	<b>&lt;.0001</b>	<b>0.0395</b>


612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627





628 **Table 2. Demographics and Comorbidities of the Study Population**  
629

		<b>Control</b>	<b>HFpEF</b>	<b>HFrEF</b>	<b>Control vs. HFpEF p-value</b>	<b>Control vs. HFrEF p-value</b>	<b>HFpEF vs. HFrEF p-value</b>
<b>Race</b>	<b>White</b>	134(63.5%)	222(62.2%)	123(56.6%)	0.69	0.29	0.15
	<b>Black</b>	69(32.7%)	125(35%)	82(37.4%)			
	<b>Asian</b>	1(.5%)	3(.84%)	4(1.8%)			
	<b>Other</b>	7(3.3%)	7(1.96%)	10(4.6%)			
<b>Sex</b>	<b>Male</b>	120(56.9%)	185(51.8%)	155(70.8%)	0.26	<b>0.004</b>	<b>&lt;.0001</b>
	<b>Female</b>	91(43.1%)	172(48.2%)	64(29.2%)			
	<b>Type 2 Diabetes (%)</b>	33(15.6%)	163(45.7%)	75(34.2%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	<b>0.0069</b>
	<b>Hypertension (%)</b>	103(48.8%)	283(79.2%)	161(73.5%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	0.11
	<b>Hyperlipidemia (%)</b>	99(46.9%)	260(72.8%)	157(71.7%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	0.76
	<b>Atrial Fibrillation (%)</b>	16(7.6%)	202(56.6%)	100(45.7%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	<b>0.011</b>
	<b>Chronic Kidney Disease (%)</b>	13(6.2%)	100(28%)	77(35.2%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	0.07
	<b>COPD (%)</b>	16(7.6%)	100(28%)	40(18.3%)	<b>&lt;.0001</b>	<b>0.001</b>	<b>0.008</b>
	<b>Any Cancer (%)</b>	6(2.8%)	98(27.5%)	49(22.4%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	0.2
	<b>Prior MI (%)</b>	4(1.9%)	44(12.3%)	50(22.8%)	<b>&lt;.0001</b>	<b>&lt;.0001</b>	<b>0.001</b>


630




**Figure 1. Unsaturated MCAC and LCAC species are elevated in HFrfEF but not HFpEF.** Radar plots of MCACs (left) and LCACs (right) depicting plasma levels of acylcarnitines in HFpEF (grey) and HFrfEF (black) as percentages of control. Symbols indicate significance of comparisons across groups.

**A.****B.**


**Figure 2. Plasma metabolome in both HFrfEF and HFpEF subjects reflect increased BCAA degradation.** **A)** Radar plot depicting plasma levels of branched-chain amino acids (BCAA) and BCAA metabolites in HFpEF (grey) and HFrfEF (black) as percentages of control. Symbols indicate significance of comparisons across groups. **B)** Diagram displaying the BCAA metabolic pathway. Metabolites in bold represent acylcarnitine species measured in this study. SCAC correlates are indicated in parenthesis.




**Figure 3. Levels of a subset of amino acids are elevated in the plasma of HF patients.** Radar plot depicting plasma levels of amino acids in HFpEF (grey) and HFrEF (black) as percentages of control. Symbols indicate significance of comparisons across groups. Notably elevated species included 1- and 3-methylhistidine, symmetric dimethylarginine (SDMA), asymmetric dimethylarginine (ADMA), and homocitrulline.



**Figure 4. Asymmetric dimethylarginine is uniquely elevated in HFpEF while homocitrulline is elevated in both forms of HF.** **A)** Metabolic pathway depicting the formation of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) and subsequently their effects on arginine metabolism. **B)** Bar graphs depicting mean  $\pm$  SD of serum concentrations of Arginine (left), SDMA (middle), and ADMA (right) by cohort. Asterisk indicates  $p$ -value  $< .05$ . **C)** Metabolic pathway depicting the formation of homocitrulline residues from the incorporation of isocyanate into proteins with lysine residues. **D)** Bar graph depicting mean  $\pm$  SD of serum concentrations of Homocitrulline by cohort, showing significant elevation in HFREF. Asterisk indicates  $p$ -value  $< .05$ .



**Figure 5. Plasma levels of ketone body 3-hydroxybutyrate (3-HBA), and its downstream metabolite, C4-OH carnitine, are uniquely elevated in HFrEF subjects.** **A)** Radar plot depicting plasma levels of organic acids in HFpEF (grey) and HFrEF (black) as percentages of control. Symbols indicate significance of comparisons across groups. **B)** Bar graphs depicting mean  $\pm$  SD of serum concentrations 3-HBA (top) and its metabolite C4-OH carnitine (bottom), which are both uniquely elevated in HFrEF. Asterisks indicate  $p$ -value  $< .05$ .



**Figure 6. NT-proBNP is significantly elevated in HFrEF and is correlated with levels of 3-HBA in patients with HF but not in the Control group.** **A)** Bar graphs depicting mean  $\pm$  SD of transformed concentration of plasma NT-proBNP in controls, HFpEF, and HFrEF. Asterisks indicate  $p$ -value  $< .05$ . **B)** Linear regressions depicting the relationship between the plasma concentration of 3-HBA and the transformed plasma concentration of NT-proBNP within control (top left), HFpEF (top right), and HFrEF (bottom). **C)** Proposed mechanism by which BNP indirectly acts to increase serum acylcarnitines and ketone bodies. In response to volume overload and increasing wall stress, the failing heart secretes natriuretic peptides, including BNP. BNP is known to act on adipocytes to increase lipolysis, leading to increased serum FFA and triglycerides. Subsequently, the liver oxidizes the FAs generating increased levels of acylcarnitine intermediates and acetyl-CoA, the latter serving as a substrate for ketone synthesis. Created with BioRender.com.